Literature DB >> 10891990

Novel prion protein gene mutation in an octogenarian with Creutzfeldt-Jakob disease.

S Collins1, A Boyd, A Fletcher, K Byron, C Harper, C A McLean, C L Masters.   

Abstract

BACKGROUND: The transmissible spongiform encephalopathies constitute a fascinating and biologically unique group of invariably fatal neurodegenerative disorders that affect both animals and humans. Creutzfeldt-Jakob disease (CJD), Gerstmann-Straussler-Scheinker syndrome, and fatal familial insomnia represent the more common human phenotypes. Excluding the small number of iatrogenically transmitted cases, approximately 85% to 90% of patients develop CJD without identifiable explanation, with an increasing number of different mutations in the prion protein gene (PRNP) recognized as probably causative in the remainder.
OBJECTIVE: To report on an 82-year-old woman with pathologically confirmed CJD found unexpectedly to harbor a novel mutation in PRNP.
METHODS: Routine clinical investigations were undertaken to elucidate the cause of the rapidly progressive dementia and neurological decline manifested by the patient, including magnetic resonance imaging of the brain, electroencephalography, and cerebrospinal fluid analysis for the 14-3-3 beta protein. Standard postmortem neuropathological examination of the brain was performed, including immunocytochemistry of representative sections to detect the prion protein. Posthumous genetic analysis of the open reading frame of PRNP was performed on frozen brain tissue using polymerase chain reaction and direct sequencing.
RESULTS: Concomitant with the exclusion of alternative diagnoses, the presence of characteristic periodic sharp-wave complexes on the electroencephalogram in combination with a positive result for 14-3-3 beta protein in the cerebrospinal fluid led to a confident clinical diagnosis of CJD, confirmed at autopsy. There was no family history of dementia or similar neurological illness, but patrilineal medical information was incomplete. Unexpectedly, full sequencing of the PRNP open reading frame revealed a single novel mutation consisting of an adenine-to-guanine substitution at nucleotide 611, causing alanine to replace threonine at codon 188.
CONCLUSIONS: In addition to expanding the range of PRNP mutations associated with human prion diseases, we believe this case is important for the following reasons. First, from an epidemiological perspective, the avoidance of occasional incorrect classification of patients manifesting neurodegenerative disorders that may have a genetic basis requires systematic genotyping, particularly when there are uncertainties regarding the family history. Second, the incidence of spongiform encephalopathy in elderly patients beyond the typical age range may be underestimated and does not preclude a genetic basis. Finally, as a corollary, this case highlights problematic issues in human transmissible spongiform encephalopathies, as illustrated by disease penetrance and age of onset in genotype-phenotype correlations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10891990     DOI: 10.1001/archneur.57.7.1058

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  13 in total

Review 1.  Genetic PrP Prion Diseases.

Authors:  Mee-Ohk Kim; Leonel T Takada; Katherine Wong; Sven A Forner; Michael D Geschwind
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-05-01       Impact factor: 10.005

Review 2.  Hereditary Human Prion Diseases: an Update.

Authors:  Matthias Schmitz; Kathrin Dittmar; Franc Llorens; Ellen Gelpi; Isidre Ferrer; Walter J Schulz-Schaeffer; Inga Zerr
Journal:  Mol Neurobiol       Date:  2016-06-20       Impact factor: 5.590

3.  Pathologic evidence that the T188R mutation in PRNP is associated with prion disease.

Authors:  Maria Carmela Tartaglia; Julie N Thai; Tricia See; Amy Kuo; Robert Harbaugh; Benjamin Raudabaugh; Ignazio Cali; Mamta Sattavat; Henry Sanchez; Stephen J DeArmond; Michael D Geschwind
Journal:  J Neuropathol Exp Neurol       Date:  2010-12       Impact factor: 3.685

Review 4.  Genetic prion disease: Experience of a rapidly progressive dementia center in the United States and a review of the literature.

Authors:  Leonel T Takada; Mee-Ohk Kim; Ross W Cleveland; Katherine Wong; Sven A Forner; Ignacio Illán Gala; Jamie C Fong; Michael D Geschwind
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2017-01       Impact factor: 3.568

5.  Human Prion disease with a T188K mutation in Chinese: a case report.

Authors:  Qi Shi; Chen Gao; Wei Zhou; Bao-Yun Zhang; Chan Tian; Jian-Ming Chen; Hui-Ying Jiang; Jun Han; Xiao-Ping Dong
Journal:  Cases J       Date:  2009-05-29

Review 6.  Anaesthesia in elderly patients with neurodegenerative disorders: special considerations.

Authors:  Deborah A Burton; Grainne Nicholson; George M Hall
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 7.  Protein folding pathology in domestic animals.

Authors:  Erik Gruys
Journal:  J Zhejiang Univ Sci       Date:  2004-10

8.  Novel mutation of the PRNP gene of a clinical CJD case.

Authors:  Konstantia Kotta; Ioannis Paspaltsis; Sevasti Bostantjopoulou; Helen Latsoudis; Andreas Plaitakis; Dimitrios Kazis; John Collinge; Theodoros Sklaviadis
Journal:  BMC Infect Dis       Date:  2006-11-27       Impact factor: 3.090

9.  Evidence for a pathogenic role of different mutations at codon 188 of PRNP.

Authors:  Sigrun Roeber; Eva-Maria Grasbon-Frodl; Otto Windl; Bjarne Krebs; Wei Xiang; Caren Vollmert; Thomas Illig; Andreas Schröter; Thomas Arzberger; Petra Weber; Inga Zerr; Hans A Kretzschmar
Journal:  PLoS One       Date:  2008-05-14       Impact factor: 3.240

10.  Cerebrospinal fluid biomarkers in human genetic transmissible spongiform encephalopathies.

Authors:  Anna Ladogana; Pascual Sanchez-Juan; Eva Mitrová; Alison Green; Natividad Cuadrado-Corrales; Raquel Sánchez-Valle; Silvia Koscova; Adriano Aguzzi; Theodoros Sklaviadis; Jerzy Kulczycki; Joanna Gawinecka; Albert Saiz; Miguel Calero; Cornelia M van Duijn; Maurizio Pocchiari; Richard Knight; Inga Zerr
Journal:  J Neurol       Date:  2009-05-15       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.